杏联药业(苏州)有限公司(简称“杏联药业")注册成立于2018年7月，注册资本20000万元，是一家立足中国、面向全球的创新型抗体药物研发、生产企业，专注于研究、发展、制造及商业化免疫性疾病疗法且主要研制以单克隆抗体为基础的生物药，致力成为开发创新药以填补未满足医疗需求的*生物制药公司。杏联药业是苏州工业园区科技重大*项目，由香港联交所主板上市企业中国抗体制药有限公司(简称“中国抗体”，股票代码:03681HK)全资设立，是其在内地研发、生产、销售及运营的总部和产业化基地。
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
